GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
19 Apr 2017 01:27 PM
RNS
Director/PDMR Shareholding
19 Apr 2017 01:21 PM
RNS
Director/PDMR Shareholding
18 Apr 2017 04:13 PM
RNS
Director/PDMR Shareholding
18 Apr 2017 09:16 AM
RNS
GSK vaccine submission for shingles in Japan
11 Apr 2017 05:26 PM
RNS
Director/PDMR Shareholding
11 Apr 2017 12:02 PM
RNS
Change to financial reporting framework
03 Apr 2017 11:26 AM
RNS
Total Voting Rights
31 Mar 2017 11:04 AM
RNS
Phase 3 study start of mepolizumab in severe HES
30 Mar 2017 01:00 PM
RNS
Notice of AGM
23 Mar 2017 04:55 PM
RNS
Director/PDMR Shareholding
21 Mar 2017 12:19 PM
RNS
Director/PDMR Shareholding
20 Mar 2017 07:00 AM
RNS
GSK 2016 Form 20F
16 Mar 2017 04:13 PM
RNS
Director/PDMR Shareholding
15 Mar 2017 05:07 PM
RNS
Director/PDMR Shareholding
14 Mar 2017 01:00 PM
RNS
Publication of 2016 Annual Financial Report
10 Mar 2017 04:10 PM
RNS
Director/PDMR Shareholding
08 Mar 2017 04:26 PM
RNS
Director/PDMR Shareholding
06 Mar 2017 04:51 PM
RNS
Director/PDMR Shareholding
06 Mar 2017 02:49 PM
RNS
GSK's MUSCA study results on Nucala (mepolizumab)
01 Mar 2017 10:06 AM
RNS
Total Voting Rights
23 Feb 2017 03:07 PM
RNS
Director/PDMR Shareholding
23 Feb 2017 02:57 PM
RNS
Director/PDMR Shareholding
23 Feb 2017 09:59 AM
RNS
Positive results for Relvar Ellipta Lung Study
22 Feb 2017 01:58 PM
RNS
Director/PDMR Shareholding
21 Feb 2017 05:14 PM
RNS
Director/PDMR Shareholding
20 Feb 2017 03:55 PM
RNS
Director/PDMR Shareholding
20 Feb 2017 02:12 PM
RNS
Director/PDMR Shareholding
17 Feb 2017 03:58 PM
RNS
Director/PDMR Shareholding
17 Feb 2017 03:57 PM
RNS
Director/PDMR Shareholding
17 Feb 2017 03:55 PM
RNS
Director/PDMR Shareholding
15 Feb 2017 05:15 PM
RNS
Director/PDMR Shareholding
14 Feb 2017 12:43 PM
RNS
Director/PDMR Shareholding
14 Feb 2017 09:49 AM
RNS
Director/PDMR Shareholding
14 Feb 2017 07:00 AM
RNS
ViiV Phase III results Dolutegravir & Rilpivirine
13 Feb 2017 05:04 PM
RNS
Director/PDMR Shareholding
10 Feb 2017 03:47 PM
RNS
Director/PDMR Shareholding
10 Feb 2017 11:10 AM
RNS
Director/PDMR Shareholding
10 Feb 2017 08:42 AM
RNS
Blocklisting Application
09 Feb 2017 05:32 PM
RNS
Director/PDMR Shareholding
09 Feb 2017 01:42 PM
RNS
Director/PDMR Shareholding
08 Feb 2017 05:27 PM
RNS
Director/PDMR Shareholding
08 Feb 2017 12:00 PM
RNS
Final Results
01 Feb 2017 11:02 AM
RNS
Total Voting Rights
25 Jan 2017 04:17 PM
RNS
Director/PDMR Shareholding
24 Jan 2017 04:51 PM
RNS
Director/PDMR Shareholding
23 Jan 2017 03:45 PM
RNS
Director/PDMR Shareholding
20 Jan 2017 03:07 PM
RNS
Director/PDMR Shareholding
19 Jan 2017 07:05 AM
RNS
Corporate executive team changes
19 Jan 2017 07:00 AM
RNS
Corporate executive team changes
16 Jan 2017 06:25 PM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings